Industry Newsbiopharmaoncologymerckm a
Merck Ends Acquisition Talks RVMD Stock Plunges
6.2
Revolution Medicines shares fell 16.91% to $97.78 on Monday after reports that Merck canceled acquisition talks following valuation disagreements; Merck had sought $28–32 billion. The company is advancing RAS-targeted experimental medicines and recently received an FDA Breakthrough Therapy designation for zoldonrasib, supported by Phase 1 RMC-9805-001 monotherapy data showing encouraging antitumor activity and acceptable safety.
Key Points
- 1Reports show Merck terminates acquisition talks, triggering RVMD share drop of 16.91% to $97.78.
- 2Deal collapse stemmed from valuation gap; Merck sought a $28–32 billion acquisition price.
- 3Breakthrough designation validates Phase 1 zoldonrasib results, reinforcing RVMD's RAS program value.
Scoring Rationale
Strong confirmed M&A and regulatory developments drive score, but limited relevance to core AI/ML audiences reduces impact.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
